Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01581411 · ClinicalTrials.gov registry record · Phase 1
Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01581411 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 1 participants.
The verdict
NCT01581411, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Central retinal vein occlusion (CRVO) is a common cause of vision loss, typically affecting individuals during the fifth through seventh decade of life. Eyes with severe CRVO have a poor visual prognosis because current treatments address only secondary complications of CRVO without treating its cause. Intra-ophthalmic artery injection of a small dose of t-PA (clot busting medicine), also called intra-ophthalmic artery thrombolysis, may reopen the central retinal vein-and address the cause of the disease- without exposing the subject to the risks of systemic thrombolysis. Our project aims to evaluate the safety and efficacy of intra-ophthalmic artery thrombolysis in subjects with CRVO.
Interventions
- DRUG Tissue Plasminogen Activator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01581411
The ClinicalTrials.gov registry entry for NCT01581411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tissue Plasminogen Activator is the first listed.
NCT01581411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01581411 about?
NCT01581411 is a clinical study titled "Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion". Central retinal vein occlusion (CRVO) is a common cause of vision loss, typically affecting individuals during the fifth through seventh decade of life. Eyes with severe CRVO have a poor visual prognosis because current treatments address only secondary complications of CRVO without treating its cau...
What is the current status of trial NCT01581411?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01581411?
The interventions under investigation include: Tissue Plasminogen Activator (DRUG).
Who is sponsoring clinical trial NCT01581411?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.